en · de · es · pt
melanotan-2-notes.peptides3626.com › Wiki › Background And Chemical Profile — Hands-On Walkthrough

Background And Chemical Profile — Hands-On Walkthrough

By Editorial Desk · published 2026-04-03 · last reviewed 2026-05-24 · Wiki

The short version of lactam bridge fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-05-24 and is reviewed periodically as new material appears.

Background and Chemical Profile

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.

Peptide Identity and Structural Background

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 at a glance

PropertyValueNotes
Molecular classSynthetic cyclic heptapeptideAnalog of alpha-MSH with an internal lactam bridge
Molecular weightApproximately 1024 daltonsFree base value; salt forms differ
AppearanceWhite to off-white powderUsually supplied as a lyophilized solid
SolubilityFreely soluble in waterPoorly soluble in nonpolar solvents
Typical storage−20 °C, dry, protected from lightRepeated freeze-thaw cycles degrade peptides

Melanotan II Background and Mechanism

Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.

Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.

Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.

Related pages on this site

Background from the literature

In many ways, early Knoxville was a typical rowdy late-18th century frontier village. A detached group of Cherokee, known as the Chickamaugas, refused to recognize the Holston treaty, and remained a constant threat. In September 1793, a large force of Chickamaugas and Creeks marched on Knoxville, and massacred the inhabitants of Cavet's Station (near modern Bearden) before dispersing. Outlaws roamed the city's periphery, among them the Harpe Brothers, who murdered at least one settler in 1797 before fleeing to Kentucky. Abishai Thomas, an associate of Blount who visited Knoxville in 1794, noted that the city was full of taverns and tippling houses, no churches, and that the blockhouse's jail was overcrowded with criminals. In 1795, James White set aside more land for the growing city, allowing it to expand northward to modern Clinch Avenue and westward to modern Henley Street. A census that year showed that Tennessee had a large enough population to apply for statehood. In January 1796, delegates from across Tennessee, including Blount, Sevier, and Andrew Jackson, convened in Knoxville to draw up a constitution for the new state, which was admitted to the Union on June 1, 1796. Knoxville was chosen as the initial capital of the state.

=== EGFR side effects === Epidermal growth factor receptor (EGFR) inhibitors are medications used in cancer treatment. These medications commonly cause skin and nail problems, including rashes, dry skin and paronychia. Preventive intensive moisturizing with emollient ointments several times, avoidance of water-based creams and water soaks (although in certain circumstances white vinegar or potassium permanganate soaks may help), protection the skin from excessive exposure to sunshine, and soap substitutes which are less dehydrating for the skin than normal soaps, as well as shampoos that reduce the risk of scalp folliculitis, are recommended. Treatment measures with topical antibiotic medication can be helpful.

=== Function in pregnancy === Human placental lactogen (hPL) plays a role in supporting the changes needed during pregnancy. It helps in the development of the mammary glands for milk production post-childbirth. Additionally, with estrogen and progesterone, hPL helps in growing alveolar for lactogenesis. Acting as a growth hormone it facilitates fetal development by boosting protein synthesis and cellular growth.

== Research == Alström Syndrome was first discovered by Swedish psychiatrist, Carl-Henry Alström and his three associates, B. Hallgren, I. B. Nilsson and H. Asander, in 1946. Alström and his colleagues published their first manuscript in 1959, which contained a very thorough investigation of three patients with a recessive combination of retinal degeneration, obesity, sensorineural hearing loss, and diabetes, which are all extremely common symptoms in AS. The syndrome was first known as Alström-Hallgren Syndrome, but has since been more widely known as just Alström Syndrome. In 2001 Jackson Laboratory in Bar Harbor, Maine, USA with the University of Southampton, UK isolated the single gene (ALMS1) responsible for Alström syndrome. The Jackson Laboratory created the very first mouse model for AS, Alms1-/-, or more colloquially known as "Carl Henry Mouse" in 2004. These mice continue to be used in research studies to simulate the symptoms of an individual with AS.

Sources: en.wikipedia.org

Reference notes

== Diagnosis == Skin changes, abnormal growth, and loss of hair occur. These symptoms normally start appearing by one year of age. A genetic test for LMNA mutations can confirm the diagnosis of progeria. Prior to the advent of the genetic test, misdiagnosis was common.

== External links == Archer J.P. Martin on Nobelprize.org Portraits of Archer Martin at the National Portrait Gallery, London Martin's Nobel lecture: The Development of Partition Chromatography M Martin's Column's: Classic Kit

=== Solvent === Solvents are usually chosen based on the applications of the gel. They can be hydrophilic, lipophilic, or organic. Individual solvents can be used alone or as a mixture. Some examples of solvents include purified water, glycerin, glycols, alcohols, sucrose, toluene, and mineral oils.

=== Nutrient delivery system === Immunoliposomes can also be used as nutrient delivery systems to help stimulate brain activity. The effective transport of certain nutrients to the hypothalamus in order to regulate brain activity is currently a huge problem. The leptin gene is used to regulate feedback loops and send signals from the adipose tissue to the hypothalamus. Using this physiological function of leptin, immunoliposome nutrient delivery systems can be integrated into the body to help with nutrition transport to the brain as seen in Figure 5. Transferrin receptors have high expression at the BBB (blood brain barrier) and can be used as targets for immunoliposomes to transport p-glycoprotein substances.

== Reactions == Having a pKa value of around 0, TFA does not exist as such at concentrations found in natural waters. Instead TFA converts to trifluoroacetate, concomitant with the protonation of water. It protonates several weakly basic anions, e.g. azide to give hydrazoic acid.

Sources: en.wikipedia.org

Notes from published material

== Management of intoxication == Management of PCP intoxication mostly consists of supportive care – controlling breathing, circulation, and body temperature – and, in the early stages, treating psychiatric symptoms. Benzodiazepines, such as lorazepam, are the drugs of choice to control agitation and seizures (when present). Typical antipsychotics such as phenothiazines and haloperidol have been used to control psychotic symptoms, but may produce many undesirable side effects – such as dystonia – and their use is therefore no longer preferred; phenothiazines are particularly risky, as they may lower the seizure threshold, worsen hyperthermia, and boost the anticholinergic effects of PCP. If an antipsychotic is given, intramuscular haloperidol has been recommended. Forced acid diuresis (with ammonium chloride or, more safely, ascorbic acid) may increase the clearance of PCP from the body, and was somewhat controversially recommended in the past as a decontamination measure. However, it is now known that only around 10% of a dose of PCP is removed by the kidneys, which would make increased urinary clearance of little consequence; furthermore, urinary acidification is dangerous, as it may induce acidosis and worsen rhabdomyolysis (muscle breakdown), a not-unusual manifestation of PCP toxicity.

Treosulfan, sold under the brand name Trecondi among others, is an alkylating medication given to people before they have a bone marrow transplant from a donor known as allogeneic hematopoietic stem cell transplantation. It is used as a 'conditioning' treatment to clear the bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells. It is used together with another medicine called fludarabine in adults and children from one month of age with blood cancers as well as in adults with other severe disorders requiring a bone marrow transplant. It belongs to the family of drugs called alkylating agents. In the body, treosulfan is converted into other compounds called epoxides which kill cells, especially cells that develop rapidly such as bone marrow cells, by attaching to their DNA while they are dividing. DNA cross-linking is considered a primary mechanism underlying the pharmacological action of treosulfan, and epoxides formed from treosulfan may cross-link DNA via at least two chemical pathways. Preclinical studies in animal models have shown that treosulfan is widely distributed to the liver, lungs, bone marrow, and skeletal muscle, with tissue-to-plasma ratios of 0.96, 0.82, 0.82, and 0.77, respectively. Lower biodistribution was observed in the brain and the aqueous humor of the eye (both 0.10). In juvenile rats with an immature blood–brain barrier, brain exposure was higher (0.15) than in young adult rats.

=== Fatty Acid Synthesis === Fatty acid synthesis begins in the cytosol. During the first reaction, irreversible carboxylation of acetyl-CoA to malonyl-CoA is catalyzed by the biotin-dependent enzyme acetyl-CoA carboxylase (ACC). Notably, the conversion of acetyl-CoA to malonyl-CoA is the rate-limiting step of fatty acid synthesis. Acetyl-CoA carboxylase (ACC) thus represents the rate-limiting enzyme in fatty acid synthesis; ACC activity is stimulated by increasing concentrations of cytosolic citrate, and inhibited by increasing concentrations of the fatty acid palmitate. After malonyl-CoA becomes available by virtue of ACC, fatty acid synthase (FAS) is then able to complete a series of reactions to form the 16-carbon molecule palmitate. FAS is a complex, multifunctional protein containing seven different catalytic sites: acetyl transacylase, malonyl transacylase, β-ketoacyl synthase, β-ketoacyl carrier protein (ACP) reductase, 3-hydroxyacyl-ACP dehydratase, enoyl-ACP reductase, and thioesterase. These different enzymes are covalently linked within the FAS complex, allowing for intermediates to be handled efficiently from one active site to another without leaving the assembly. After the completion of the first reaction by ACC, fatty acid synthesis thus continues on the FAS complex. During the second reaction of fatty acid synthesis, acetyl transacylase and malonyl transacylase catalyze the formation of acetyl-ACP and malonyl-ACP, respectively.

The South African Border War, also known as the Namibian War of Independence, and sometimes denoted in South Africa as the Angolan Bush War, was a largely asymmetric conflict that occurred in Namibia (then South West Africa), Zambia, and Angola from 26 August 1966 to 21 March 1990. It was fought between the South African Defence Force (SADF) and the People's Liberation Army of Namibia (PLAN), an armed wing of the South West African People's Organisation (SWAPO). The South African Border War was closely intertwined with the Angolan Civil War.

First generation vaccines are whole-organism vaccines – either live and weakened, or killed forms. Live, attenuated vaccines, such as smallpox and polio vaccines, are able to induce killer T-cell (TC or CTL) responses, helper T-cell (TH) responses and antibody immunity. However, attenuated forms of a pathogen can convert to a dangerous form and may cause disease in immunocompromised vaccine recipients (such as those with AIDS). While killed vaccines do not have this risk, they cannot generate specific killer T-cell responses and may not work at all for some diseases. Second generation vaccines were developed to reduce the risks from live vaccines. These are subunit vaccines, consisting of specific protein antigens (such as tetanus or diphtheria toxoid) or recombinant protein components (such as the hepatitis B surface antigen). They can generate TH and antibody responses, but not killer T cell responses. RNA vaccines and DNA vaccines are examples of third generation vaccines. In 2016 a DNA vaccine for the Zika virus began testing at the National Institutes of Health. Separately, Inovio Pharmaceuticals and GeneOne Life Science began tests of a different DNA vaccine against Zika in Miami. Manufacturing the vaccines in volume was unsolved as of 2016. Clinical trials for DNA vaccines to prevent HIV are underway. mRNA vaccines such as BNT162b2 were developed in the year 2020 with the help of Operation Warp Speed and massively deployed to combat the COVID-19 pandemic.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

How does it differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.

Is it the same as bremelanotide?

No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.

What is Melanotan-2 chemically?

It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.

Network